JP2017522284A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017522284A5 JP2017522284A5 JP2016572799A JP2016572799A JP2017522284A5 JP 2017522284 A5 JP2017522284 A5 JP 2017522284A5 JP 2016572799 A JP2016572799 A JP 2016572799A JP 2016572799 A JP2016572799 A JP 2016572799A JP 2017522284 A5 JP2017522284 A5 JP 2017522284A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- cyclohexyl
- potassium
- carbonate
- hydroxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims 6
- -1 [e] [1,3,2] dioxathiepine-3,3-dioxide Chemical compound 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 3
- PQXKDMSYBGKCJA-CVTJIBDQSA-N lurasidone Chemical compound C1=CC=C2C(N3CCN(CC3)C[C@@H]3CCCC[C@H]3CN3C(=O)[C@@H]4[C@H]5CC[C@H](C5)[C@@H]4C3=O)=NSC2=C1 PQXKDMSYBGKCJA-CVTJIBDQSA-N 0.000 claims 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims 2
- 239000000920 calcium hydroxide Substances 0.000 claims 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims 2
- 229960001432 lurasidone Drugs 0.000 claims 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims 2
- 239000001095 magnesium carbonate Substances 0.000 claims 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims 2
- 239000000347 magnesium hydroxide Substances 0.000 claims 2
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims 2
- MBABOKRGFJTBAE-UHFFFAOYSA-N methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 claims 2
- 239000011591 potassium Substances 0.000 claims 2
- 229910052700 potassium Inorganic materials 0.000 claims 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 2
- MSZUCXVGSQLRIL-HGPDSQILSA-N (1S,2R,6S,7R)-4-[[(1R,2R)-2-(hydroxymethyl)cyclohexyl]methyl]-4-azatricyclo[5.2.1.02,6]decane-3,5-dione Chemical compound O=C([C@H]1[C@@H](C2=O)[C@]3([H])CC[C@]1(C3)[H])N2C[C@@H]1CCCC[C@H]1CO MSZUCXVGSQLRIL-HGPDSQILSA-N 0.000 claims 1
- RIVOBMOBWMOLDJ-RNGGSSJXSA-N (3ar,4s,7r,7as)-hexahydro-1h-4,7-methanoisoindole-1,3(2h)-dione Chemical compound O=C1NC(=O)[C@@H]2[C@H]1[C@]1([H])C[C@@]2([H])CC1 RIVOBMOBWMOLDJ-RNGGSSJXSA-N 0.000 claims 1
- OQYOVYWFXHQYOP-UHFFFAOYSA-N 1,3,2-dioxathiane 2,2-dioxide Chemical compound O=S1(=O)OCCCO1 OQYOVYWFXHQYOP-UHFFFAOYSA-N 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- KRDOFMHJLWKXIU-UHFFFAOYSA-N ID11614 Chemical compound C1CNCCN1C1=NSC2=CC=CC=C12 KRDOFMHJLWKXIU-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical group [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 claims 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 claims 1
- 150000008052 alkyl sulfonates Chemical class 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 230000002152 alkylating effect Effects 0.000 claims 1
- 230000029936 alkylation Effects 0.000 claims 1
- 238000005804 alkylation reaction Methods 0.000 claims 1
- 239000011260 aqueous acid Substances 0.000 claims 1
- 125000005228 aryl sulfonate group Chemical group 0.000 claims 1
- 239000011575 calcium Chemical group 0.000 claims 1
- 229910052791 calcium Chemical group 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 claims 1
- 239000011777 magnesium Chemical group 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 claims 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 claims 1
- 239000011734 sodium Chemical group 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462012701P | 2014-06-16 | 2014-06-16 | |
| US62/012,701 | 2014-06-16 | ||
| PCT/US2015/035558 WO2015195478A1 (en) | 2014-06-16 | 2015-06-12 | Processes for making alkylated arylpiperazine and alkylated arylpiperidine compounds including novel intermediates |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017522284A JP2017522284A (ja) | 2017-08-10 |
| JP2017522284A5 true JP2017522284A5 (cg-RX-API-DMAC7.html) | 2019-03-14 |
| JP6594351B2 JP6594351B2 (ja) | 2019-10-23 |
Family
ID=54835598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016572799A Active JP6594351B2 (ja) | 2014-06-16 | 2015-06-12 | 新規中間体を含むアルキル化アリールピペラジン及びアルキル化アリールピペリジン化合物の製造方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US9790237B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3154967B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6594351B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2951917C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2826603T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20201638T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE052277T2 (cg-RX-API-DMAC7.html) |
| PL (1) | PL3154967T3 (cg-RX-API-DMAC7.html) |
| SI (1) | SI3154967T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015195478A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL233778B1 (pl) | 2016-07-19 | 2019-11-29 | Adamed Spolka Z Ograniczona Odpowiedzialnoscia | Sposob wytwarzania brekspiprazolu oraz zastosowanie zwiazkow posrednich w sposobie wytwarzania brekspiprazolu |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| CN116848108A (zh) * | 2021-03-31 | 2023-10-03 | 四川科伦药物研究院有限公司 | 一种鲁拉西酮可注射混悬液及其制备方法 |
| CN115073444A (zh) * | 2022-08-05 | 2022-09-20 | 山东科源制药股份有限公司 | 一种盐酸鲁拉西酮环氧杂质的精制去除方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE967826C (de) | 1954-06-14 | 1957-12-19 | Henkel & Cie Gmbh | Verfahren zur Herstellung von Aryloxyalkanol-schwefelsaeurehalbestersalzen |
| GB1511159A (en) * | 1975-07-10 | 1978-05-17 | Leo A | Amines preparation |
| US5153206A (en) | 1988-12-02 | 1992-10-06 | Pfizer Inc. | Arylpiperidine derivatives |
| JP2800953B2 (ja) | 1990-07-06 | 1998-09-21 | 住友製薬株式会社 | 新規なイミド誘導体 |
| US5159100A (en) | 1990-12-19 | 1992-10-27 | Lonza Ltd. | Process for the production of cyclopropanenitrile derivatives |
| US6467121B1 (en) | 2000-08-15 | 2002-10-22 | Goodway Technologies Corporation | Rotary tube scrubber |
| UA79300C2 (en) | 2002-08-12 | 2007-06-11 | Janssen Pharmaceutica Nv | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion |
| JP4745661B2 (ja) | 2002-08-22 | 2011-08-10 | 大日本住友製薬株式会社 | 統合失調症治療剤 |
| KR101085806B1 (ko) | 2003-07-29 | 2011-11-22 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 이미드 화합물의 제조 방법 |
| US20060257987A1 (en) * | 2003-08-20 | 2006-11-16 | Gonzalez Valcarcel Isabel Cris | Ppar modulators |
| US7276610B2 (en) | 2003-08-27 | 2007-10-02 | Janssen Pharaceutica, Nv | Aryl piperidine amides |
| WO2005080976A1 (ja) | 2004-02-20 | 2005-09-01 | Dainippon Sumitomo Pharma Co., Ltd. | 統合失調症の記憶・学習機能障害治療薬のin vivoスクリーニング方法 |
| ES2390353T3 (es) | 2005-06-13 | 2012-11-12 | Dainippon Sumitomo Pharma Co., Ltd. | Preparación de disolución |
| KR101077423B1 (ko) | 2006-08-17 | 2011-10-26 | 에프. 호프만-라 로슈 아게 | 아릴피페라진 유도체 및 그의 용도 |
| US20090076027A1 (en) | 2007-09-17 | 2009-03-19 | Protia, Llc | Deuterium-enriched lurasidone |
| CN101868228B (zh) | 2007-11-21 | 2016-12-07 | 大日本住友制药株式会社 | 口腔内崩解片 |
| US8735397B2 (en) | 2010-03-29 | 2014-05-27 | Vanderbilt University | Method for treating schizophrenia and related diseases |
| JP5820822B2 (ja) | 2010-04-26 | 2015-11-24 | 大日本住友製薬株式会社 | リン酸塩を用いる第四級アンモニウム塩の製造法 |
| HUE030294T2 (en) | 2010-04-26 | 2017-04-28 | Sumitomo Dainippon Pharma Co Ltd | A method for preparing a quaternary ammonium salt |
| US8258139B2 (en) | 2010-11-08 | 2012-09-04 | Dainippon Sumitomo Pharma Co., Ltd. | Method of treatment for mental disorders |
| WO2012063246A1 (en) | 2010-11-11 | 2012-05-18 | Mapi Pharma Ltd. | Amorphous form of lurasidone hydrochloride |
| WO2012107890A2 (en) | 2011-02-10 | 2012-08-16 | Ranbaxy Laboratories Limited | Crystalline forms of lurasidone hydrochloride |
| WO2012123858A1 (en) | 2011-03-14 | 2012-09-20 | Ranbaxy Laboratories Limited | Amorphous lurasidone hydrochloride |
| EP2694499A1 (en) | 2011-04-01 | 2014-02-12 | Ranbaxy Laboratories Limited | Process for the preparation of an antipsychotic agent |
| CA2836066A1 (en) | 2011-05-13 | 2012-11-22 | Dainippon Sumitomo Pharma Co., Ltd. | Treatment and management of cns disorders |
| US8981095B2 (en) * | 2011-07-28 | 2015-03-17 | Mapi Pharma Ltd. | Intermediate compounds and process for the preparation of lurasidone and salts thereof |
| WO2013030722A1 (en) | 2011-08-26 | 2013-03-07 | Ranbaxy Laboratories Limited | Crystalline lurasidone hydrochloride |
-
2015
- 2015-06-12 EP EP15731459.2A patent/EP3154967B1/en active Active
- 2015-06-12 PL PL15731459T patent/PL3154967T3/pl unknown
- 2015-06-12 HR HRP20201638TT patent/HRP20201638T1/hr unknown
- 2015-06-12 WO PCT/US2015/035558 patent/WO2015195478A1/en not_active Ceased
- 2015-06-12 SI SI201531384T patent/SI3154967T1/sl unknown
- 2015-06-12 JP JP2016572799A patent/JP6594351B2/ja active Active
- 2015-06-12 ES ES15731459T patent/ES2826603T3/es active Active
- 2015-06-12 HU HUE15731459A patent/HUE052277T2/hu unknown
- 2015-06-12 CA CA2951917A patent/CA2951917C/en active Active
- 2015-06-12 US US14/737,599 patent/US9790237B2/en active Active
-
2017
- 2017-10-16 US US15/784,585 patent/US9957283B1/en active Active
-
2018
- 2018-04-20 US US15/958,645 patent/US20180312530A1/en not_active Abandoned